Edition:
United Kingdom

Avid Bioservices Inc (CDMO.OQ)

CDMO.OQ on NASDAQ Stock Exchange Capital Market

4.78USD
16 Nov 2018
Change (% chg)

$-0.01 (-0.21%)
Prev Close
$4.79
Open
$4.75
Day's High
$4.91
Day's Low
$4.75
Volume
46,206
Avg. Vol
122,809
52-wk High
$8.40
52-wk Low
$2.25

Latest Key Developments (Source: Significant Developments)

Avid Bioservices Announces Appointment Of Daniel Hart As CFO
Tuesday, 17 Jul 2018 

July 17 (Reuters) - Avid Bioservices Inc ::AVID BIOSERVICES ANNOUNCES APPOINTMENT OF DANIEL HART AS CHIEF FINANCIAL OFFICER.AVID BIOSERVICES INC - HART MOST RECENTLY SERVED AS CFO OF ENO HOLDINGS INC.  Full Article

Peregrine Pharmaceuticals Appoints Roger Lias As President And CEO
Tuesday, 26 Dec 2017 

Dec 26 (Reuters) - Peregrine Pharmaceuticals Inc ::PEREGRINE PHARMACEUTICALS ANNOUNCES APPOINTMENT OF ROGER J. LIAS, PH.D., AS PRESIDENT AND CHIEF EXECUTIVE OFFICER.PEREGRINE PHARMACEUTICALS INC- LIAS SUCCEEDS STEVEN KING WHO RESIGNED AS PRESIDENT AND CEO.  Full Article

Peregrine Pharma reports Q2 shr loss $0.31
Monday, 11 Dec 2017 

Dec 11 (Reuters) - Peregrine Pharmaceuticals Inc ::PEREGRINE PHARMACEUTICALS REPORTS FINANCIAL RESULTS FOR SECOND QUARTER OF FISCAL YEAR 2018 AND RECENT DEVELOPMENTS.Q2 LOSS PER SHARE $0.31.- COMPANY MAINTAINS ITS MANUFACTURING REVENUE GUIDANCE FOR FULL FY 2018 OF $50 MILLION - $55 MILLION.- CONSOLIDATED NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS WAS $14.1 MILLION OR $0.31 PER SHARE, FOR Q2 OF FY 2018.  Full Article

Peregrine Pharma, Ronin Trading And SW Investment Management Announce Settlement Agreement
Tuesday, 28 Nov 2017 

Nov 28 (Reuters) - Peregrine Pharmaceuticals Inc ::PEREGRINE PHARMACEUTICALS, RONIN TRADING AND SW INVESTMENT MANAGEMENT ANNOUNCE SETTLEMENT AGREEMENT.PEREGRINE PHARMACEUTICALS - CO, ‍RONIN TRADING, SW INVESTMENT MANAGEMENT ENTERED SETTLEMENT REGARDING COMPOSITION OF PEREGRINE'S BOARD, AMONG OTHERS.PEREGRINE PHARMACEUTICALS - ON NOV 27, DIRECTORS STEVEN KING,CARLTON JOHNSON,ERIC SWARTZ & DAVID POHL TENDERED RESIGNATION IMMEDIATELY FROM BOARD​.PEREGRINE PHARMACEUTICALS - ‍VACANCIES CREATED BY THE DIRECTOR RESIGNATIONS IMMEDIATELY FILLED BY THREE INDIVIDUALS NOMINATED BY RONIN/SWIM.PEREGRINE PHARMACEUTICALS - RONIN/SWIM, WHICH COLLECTIVELY BENEFICIALLY OWNS 9.6 PERCENT OF CO, WITHDREW NOMINATION OF 6 CANDIDATES TO PEREGRINE'S BOARD​.PEREGRINE PHARMACEUTICALS - ‍RONIN/SWIM ALSO AGREED TO SOME STANDSTILL RESTRICTIONS UNTIL DATE THAT IS 30 CALENDAR DAYS AFTER 2018 ANNUAL MEETING.PEREGRINE PHARMACEUTICALS INC - ‍PEREGRINE HAS ALSO AGREED TO RE-NOMINATE A NUMBER OF RONIN/SWIM'S APPOINTEES AT 2018 ANNUAL MEETING OF STOCKHOLDERS​.  Full Article

Ronin Trading and SW Investment Management announce additional nominations to board of Peregrine pharmaceuticals
Friday, 27 Oct 2017 

Oct 27 (Reuters) - Peregrine Pharmaceuticals Inc ::Ronin Trading and SW Investment Management announce additional nominations to board of peregrine pharmaceuticals.‍ronin Trading LLC - nominating Richard B. Hancock, Joel Mccomb for election to Peregrine's board at co's 2017 annual meeting of stockholders​.Ronin Trading says reiterates "demand for peregrine to hold 2017 annual meeting without further delay​".‍Ronin Trading - co, SW Investment Management collectively own about 9.6 pct of Peregrine Pharmaceuticals Inc's outstanding shares of common stock​.  Full Article

Ronin Trading, SW Investment Management nominate James Egan to Peregrine Pharmaceuticals Board
Tuesday, 10 Oct 2017 

Oct 10 (Reuters) - Ronin Trading, LLC and SW Investment Management LLC::Ronin Trading and SW Investment Management announce additional nomination to Board of Peregrine Pharmaceuticals.Ronin Trading and SW Investment Management - ‍nomination of James (Jamie) J. Egan, for election to Peregrine's Board at co's 2017 annual meeting.‍Ronin Trading and SW Investment Management say collectively have beneficial ownership of about 8.9% of Peregrine's outstanding shares of common stock​.  Full Article

Peregrine Pharmaceuticals reports Q1 loss per share $0.06
Monday, 11 Sep 2017 

Sept 11 (Reuters) - Peregrine Pharmaceuticals Inc :Peregrine Pharmaceuticals reports financial results for first quarter of fiscal year 2018 and recent developments.Q1 loss per share $0.06.Sees Q2 2018 manufacturing revenue $50 million to $55 million.Peregrine Pharmaceuticals Inc - ‍Most of backlog is expected to be recognized during remainder of FY 2018​.Peregrine Pharmaceuticals Inc - " Avid bioservices current manufacturing revenue backlog is $33 million".Istar Inc - Company is providing manufacturing revenue guidance for full FY 2018 of $50 million - $55 million.FY2018 revenue view $56.0 million -- Thomson Reuters I/B/E/S.  Full Article

Peregrine Pharma Q2 loss per share $0.02
Monday, 12 Dec 2016 

Peregrine Pharmaceuticals Inc : Qtrly total revenue $23.4 million versus $9.5 million . Peregrine Pharmaceuticals reports financial results for second quarter of fiscal year 2017 and recent developments . Q2 loss per share $0.02 .Q2 earnings per share view $-0.03 -- Thomson Reuters I/B/E/S.  Full Article